CN Patent

CN114773320A — 1,3,5-三嗪化合物及其制备方法和用途

Assigned to Chongqing Medical University · Expires 2022-07-22 · 4y expired

What this patent protects

本发明提供一种1,3,5‑三嗪化合物及其制备方法和用途。本发明提供的1,3,5‑三嗪化合物，经检测具有较好的抑制肿TGFβR1激酶活性，可做抗肿瘤先导化合物，作为进一步开发成抗肿瘤的药物基础，在肿瘤治疗领域具有潜在、广阔的应用前景。同时，本发明制备方法简单，便于工业化生产。

USPTO Abstract

本发明提供一种1,3,5‑三嗪化合物及其制备方法和用途。本发明提供的1,3,5‑三嗪化合物，经检测具有较好的抑制肿TGFβR1激酶活性，可做抗肿瘤先导化合物，作为进一步开发成抗肿瘤的药物基础，在肿瘤治疗领域具有潜在、广阔的应用前景。同时，本发明制备方法简单，便于工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN114773320A
Jurisdiction
CN
Classification
—
Expires
2022-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Chongqing Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.